Brokers Set Expectations for DexCom, Inc.’s FY2028 Earnings (NASDAQ:DXCM)
DexCom, Inc. (NASDAQ:DXCM – Free Report) – Stock analysts at Leerink Partnrs issued their FY2028 earnings per share estimates for DexCom in a research note issued to investors on Thursday, March 28th. Leerink Partnrs analyst M. Kratky forecasts that the medical device company will post earnings of $3.97 per share for the year. The consensus estimate for DexCom’s current full-year earnings is $1.76 per share.
DexCom (NASDAQ:DXCM – Get Free Report) last posted its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the previous year, the firm posted $0.34 earnings per share. DexCom’s quarterly revenue was up 26.9% on a year-over-year basis.
Other equities research analysts have also recently issued reports about the company. Morgan Stanley increased their target price on DexCom from $101.00 to $122.00 and gave the stock an “equal weight” rating in a research note on Monday, December 4th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Tuesday. Piper Sandler increased their price target on shares of DexCom from $135.00 to $150.00 and gave the company an “overweight” rating in a report on Tuesday, December 19th. Raymond James boosted their price objective on shares of DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 23rd. Finally, Royal Bank of Canada assumed coverage on DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price for the company. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $136.67.
View Our Latest Report on DexCom
DexCom Stock Down 0.6 %
DXCM stock opened at $138.70 on Friday. The business has a 50 day moving average of $125.77 and a 200 day moving average of $112.25. The firm has a market cap of $53.47 billion, a PE ratio of 105.88, a price-to-earnings-growth ratio of 2.40 and a beta of 1.18. DexCom has a twelve month low of $74.75 and a twelve month high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18.
Insider Activity at DexCom
In related news, EVP Sadie Stern sold 2,902 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $123.63, for a total transaction of $358,774.26. Following the sale, the executive vice president now owns 79,051 shares of the company’s stock, valued at $9,773,075.13. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO Kevin R. Sayer sold 37,325 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $123.63, for a total value of $4,614,489.75. Following the completion of the sale, the chief executive officer now owns 362,841 shares in the company, valued at approximately $44,858,032.83. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Sadie Stern sold 2,902 shares of the stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $123.63, for a total value of $358,774.26. Following the sale, the executive vice president now directly owns 79,051 shares in the company, valued at approximately $9,773,075.13. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 186,259 shares of company stock valued at $24,388,086. 0.41% of the stock is owned by company insiders.
Hedge Funds Weigh In On DexCom
Several institutional investors and hedge funds have recently added to or reduced their stakes in DXCM. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of DexCom by 31.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 270,999 shares of the medical device company’s stock worth $138,643,000 after acquiring an additional 65,516 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its position in shares of DexCom by 3,596.7% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,109 shares of the medical device company’s stock worth $567,000 after purchasing an additional 1,079 shares in the last quarter. West Family Investments Inc. purchased a new position in DexCom during the 1st quarter worth $209,000. Ergoteles LLC increased its position in DexCom by 60.6% during the 1st quarter. Ergoteles LLC now owns 1,681 shares of the medical device company’s stock valued at $860,000 after buying an additional 634 shares in the last quarter. Finally, Mackenzie Financial Corp increased its holdings in shares of DexCom by 26.4% during the first quarter. Mackenzie Financial Corp now owns 29,516 shares of the medical device company’s stock valued at $15,100,000 after acquiring an additional 6,160 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.
About DexCom
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Read More
Receive News & Ratings for DexCom Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DexCom and related companies with MarketBeat.com’s FREE daily email newsletter.
